• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients].

作者信息

Kislitsyna N A

出版信息

Probl Tuberk. 1985(4):55-7.

PMID:4001111
Abstract
摘要

相似文献

1
[Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients].[利福平与异烟肼在肺结核患者肺部病理病灶中的渗透情况比较评估]
Probl Tuberk. 1985(4):55-7.
2
[Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations].[联合使用利福平与异烟肼治疗结核病时血液及切除肺组织中的药物浓度]
Probl Tuberk. 1980 Aug(8):63-5.
3
[Biotransformation of rifampicin in pulmonary tuberculosis patients].
Antibiotiki. 1977;22(2):177-80.
4
[Concentration of rifampicin in pathological formations of resected lungs].[切除肺脏病理组织中利福平的浓度]
Probl Tuberk. 1975(6):79-81.
5
[Pharmacokinetics of isoniazid, rifampicin and streptomycin in tuberculosis patients with chronic cor pulmonale].[异烟肼、利福平及链霉素在慢性肺源性心脏病肺结核患者中的药代动力学]
Probl Tuberk. 1985(10):34-7.
6
[Pharmacokinetics of rifampicin in patients with pulmonary tuberculosis].
Probl Tuberk. 1977 Apr(4):61-6.
7
On the pharmacokinetics of rifampicin I: Influence of dosage and duration of treatment with intermittent administration.
Scand J Respir Dis. 1974;55(4):229-36.
8
[Pyridoxine metabolism in pulmonary tuberculosis patients under rifampicin therapy in combination with isoniazid].[利福平联合异烟肼治疗的肺结核患者的吡哆醇代谢]
Probl Tuberk. 1982 Jan(1):58-62.
9
Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects.利福平与异烟肼间歇化疗用于肺结核的初始治疗：多种因素对副作用发生频率的影响
Tubercle. 1974 Mar;55(1):81-9.
10
[Early results of sputum-positive patients with newly-detected pulmonary tuberculosis with rifampicin combined with isoniazid and SM (preliminary report)].
Gruzlica. 1973 Jul;41(7):777-80.

引用本文的文献

1
Treatment course of cavitary pulmonary tuberculosis combined with tuberculosis in a parotid Warthin's tumor: a case report and literature review.空洞型肺结核合并腮腺沃辛瘤结核：1 例报告并文献复习
BMC Infect Dis. 2024 Nov 14;24(1):1298. doi: 10.1186/s12879-024-10193-7.
2
Lymph nodes-The neglected battlefield in tuberculosis.淋巴结——结核病被忽视的战场。
PLoS Pathog. 2020 Aug 13;16(8):e1008632. doi: 10.1371/journal.ppat.1008632. eCollection 2020 Aug.
3
Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
左氧氟沙星在耐多药结核病患者中的空洞穿透情况。
Antimicrob Agents Chemother. 2015;59(6):3149-55. doi: 10.1128/AAC.00379-15. Epub 2015 Mar 16.
4
A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.一种整合宿主免疫与抗生素动力学以研究结核病治疗的计算工具。
J Theor Biol. 2015 Feb 21;367:166-179. doi: 10.1016/j.jtbi.2014.11.021. Epub 2014 Dec 9.
5
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.抗结核药物的作用途径：从血液到病灶再到分枝杆菌细胞。
Nat Rev Microbiol. 2014 Mar;12(3):159-67. doi: 10.1038/nrmicro3200. Epub 2014 Feb 3.
6
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.药物化学家优化抗结核药物先导化合物的独特挑战
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4741-50. doi: 10.1016/j.bmcl.2013.07.006. Epub 2013 Jul 12.
7
Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs.结核分枝杆菌多磷酸盐缺乏与豚鼠对药物敏感性增强和生长受损有关。
J Bacteriol. 2013 Jun;195(12):2839-51. doi: 10.1128/JB.00038-13. Epub 2013 Apr 12.
8
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.抗结核药物在兔肺部病变中渗透的药代动力学评价。
Antimicrob Agents Chemother. 2012 Jan;56(1):446-57. doi: 10.1128/AAC.05208-11. Epub 2011 Oct 10.
9
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.用于耐多药（MDR）和广泛耐药（XDR）结核病管理的二线和三线抗结核药物的临床药理学及病灶穿透特性
Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797.
10
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.潜伏性结核的范围：重新思考生物学和干预策略。
Nat Rev Microbiol. 2009 Dec;7(12):845-55. doi: 10.1038/nrmicro2236. Epub 2009 Oct 26.